EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Retrospective, Multicenter Study of Lacosamide to Treat Neonatal Seizures

Alexandra Santana Almansa iD, Jessica R Landers iD, Nicholas S Abend, Giulia M Benedetti, Catherine J Chu, Andrew T Knox, Shavonne Massey, Steffany Moen, Andrea C Pardo iD, Arnold Sansevere, Renée A Shellhaas iD, Cameron Thomas und 4 weitere

Annals of the Child Neurology Society · 2026-03 · 4 (1) · 52-63

DOI: 10.1002/cns3.70044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Child Neurology Society, online erschienen am 19.12.2025. Verfasst von Alexandra Santana Almansa und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Boston Children's Hospital Harvard Medical School Boston Massachusetts USA. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Most antiseizure medications (ASMs) are prescribed off label for neonates. Lacosamide's efficacy in infants and availability in intravenous formulation suggest potential utility for neonates. We evaluated the safety and efficacy of lacosamide for neonatal seizures.

Methods

This 10‐center, retrospective study of neonates with seizures and lacosamide treatment initiated by ≤ 48 weeks postmenstrual age collected clinical data from medical records and electroencephalogram recordings. Lacosamide efficacy was determined by changes in seizure burden with lacosamide treatment and seizure cessation by hospital discharge. Potential adverse events were reviewed.

Results

Among 62 eligible neonates, 33 had acute provoked seizures while 29 had neonatal‐onset epilepsy; there was no difference in seizure type or baseline seizure severity between groups. There were high rates of pretreatment status epilepticus (48%) and treatment‐resistant seizures, with 93% receiving ≥ 3 ASMs before lacosamide. Most received intravenous lacosamide, with a median loading dose of 5.0 mg/kg and median daily dose of 7.3 mg/kg. Seizure cessation occurred in 37% of neonates; 21% had no additional ASM administered after lacosamide. Seizure burden, measured in seizure minutes per hour, was lower at both 4 h and 7 days following lacosamide administration. In addition, there was a median reduction in seizure frequency of 30 seizures per day at 7 and 30 days posttreatment ( p < .05). Lacosamide was continued at discharge in most neonates (72%). Seventy adverse events were reported in 35 (56%) neonates. Four transient events with possible or unknown relationship to lacosamide were likely multifactorial in origin; none were cardiac arrhythmias. Summary Despite high rates of treatment‐resistant seizures in this neonatal cohort, 37% experienced seizure cessation and most remained on lacosamide at hospital discharge. Most adverse events were not attributed to lacosamide. These results favor use of lacosamide and provide a rationale for future prospective studies.

Schlagwörter

Stichwörter der Autor:innen

antiseizure medicationlacosamideneonatal hypoxic‐ischemic encephalopathyneonatal seizuresneonatal‐onset epilepsysafety

Autor:innen und Institutionen

  • Department of Neurology, Boston Children's Hospital Harvard Medical School Boston Massachusetts USA.
  • Departments of Neurology and Pediatrics Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA.
  • Department of Pediatrics, C.S. Mott Children's Hospital University of Michigan Ann Arbor Michigan USA.
  • Department of Neurology, Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
  • Department of Neurology University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA.
  • Department of Pediatrics Sanford Health Fargo North Dakota USA.

ORCID-Profile: Alexandra Santana Almansa, Jessica R Landers, Andrea C Pardo, Renée A Shellhaas, Janet S Soul

Zitieren

APA

Almansa, A. S., Landers, J. R., Abend, N. S., Benedetti, G. M., Chu, C. J., Knox, A. T., Massey, S., Moen, S., Pardo, A. C., Sansevere, A., Shellhaas, R. A., Thomas, C., Tsuchida, T., Wang, S., Zhang, B., & Soul, J. S. (2026). Retrospective, Multicenter Study of Lacosamide to Treat Neonatal Seizures. Annals of the Child Neurology Society, 4(1), 52-63. https://doi.org/10.1002/cns3.70044

Vancouver

Almansa AS, Landers JR, Abend NS, Benedetti GM, Chu CJ, Knox AT, et al. Retrospective, Multicenter Study of Lacosamide to Treat Neonatal Seizures. Annals of the Child Neurology Society. 2026;4(1):52-63. doi:10.1002/cns3.70044

BibTeX
@article{Almansa2026,
  author = {Almansa, Alexandra Santana and Landers, Jessica R and Abend, Nicholas S and Benedetti, Giulia M and Chu, Catherine J and Knox, Andrew T and Massey, Shavonne and Moen, Steffany and Pardo, Andrea C and Sansevere, Arnold and Shellhaas, Renée A and Thomas, Cameron and Tsuchida, Tammy and Wang, Sonya and Zhang, Bo and Soul, Janet S},
  title = {Retrospective, Multicenter Study of Lacosamide to Treat Neonatal Seizures},
  journal = {Annals of the Child Neurology Society},
  year = {2026},
  volume = {4},
  number = {1},
  pages = {52--63},
  doi = {10.1002/cns3.70044}
}
Kostenlos starten →